Published in Arch Neurol on July 01, 1977
Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet (1991) 2.79
Becker's x-linked muscular dystrophy. Histological, enzyme-histochemical, and ultrastructural studies of two cases, originally reported by Becker. Acta Neuropathol (1979) 0.78
Pseudohypertrophy of muscles of thenar eminence in X-linked muscular dystrophy (Becker type). Postgrad Med J (1980) 0.75
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology (1994) 2.51
Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology (1994) 2.12
Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol (1991) 2.08
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol (1991) 2.05
Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res (1988) 1.86
Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg (1983) 1.86
Myasthenia gravis: a serum factor blocking acetylcholine receptors of the human neuromuscular junction. Lancet (1975) 1.84
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg (1991) 1.81
Detection of new paternal dystrophin gene mutations in isolated cases of dystrophinopathy in females. Am J Hum Genet (1994) 1.70
Conflicts of interest in neurology. Neurology (1998) 1.69
Effects of humidity on the development of grapevine powdery mildew. Phytopathology (2003) 1.69
Increasing incidence of primary brain lymphoma in the US. Cancer (1988) 1.68
Telomerase activity in human brain tumours. Lancet (1995) 1.64
[18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR Am J Neuroradiol (1993) 1.62
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol (1998) 1.61
Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys (1992) 1.54
Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res (1995) 1.52
Use of L-dopa in the detection of presymptomatic Huntington's chorea. N Engl J Med (1972) 1.51
Familial inclusion body myositis: evidence for autosomal dominant inheritance. Neurology (1992) 1.46
Narrowing the evidence-practice gap. Strengthening the link between research and clinical practice. Neurology (1998) 1.46
Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation (1993) 1.43
Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol (1979) 1.42
X-linked myotubular myopathy: a case report of prenatal and perinatal aspects. Pediatr Pathol (1992) 1.41
Long-term colchicine prophylaxis in children with familial Mediterranean fever (recurrent hereditary polyserositis). J Pediatr (1990) 1.40
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol (1998) 1.32
Lack of tocopherol in peripheral nerves of vitamin E-deficient patients with peripheral neuropathy. N Engl J Med (1987) 1.28
Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. Cancer Res (1982) 1.25
Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res (1997) 1.24
Increased serum creatine kinase after exercise: a sex-linked phenomenon. Neurology (1979) 1.21
Mental neuropathy from systemic cancer. Neurology (1981) 1.18
End-of-life care: a survey of US neurologists' attitudes, behavior, and knowledge. Neurology (1999) 1.16
Transient ocular motor paresis associated with acute internal carotid artery occlusion. Ann Neurol (1989) 1.15
Glycerol kinase deficiency with neuromuscular, skeletal, and adrenal abnormalities. Ann Neurol (1980) 1.15
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol (1981) 1.15
Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol (1997) 1.13
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology (1991) 1.13
Familial hyperaldosteronism, not suppressed by dexamethasone. J Clin Endocrinol Metab (1982) 1.11
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res (2001) 1.09
Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination. N Engl J Med (1980) 1.09
Neuropsychological findings in myotonic dystrophy. J Clin Neuropsychol (1982) 1.08
Diabetic muscle infarction: a new perspective on pathogenesis and management. Neuromuscul Disord (1995) 1.08
The neurologist's role in stroke management. Stroke (1996) 1.07
Myoadenylate deaminase deficiency. Muscle Nerve (1980) 1.06
Histochemistry of human extraocular muscle. Arch Ophthalmol (1978) 1.05
Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology (1996) 1.05
MRI of normal and pathologic skeletal muscle. AJR Am J Roentgenol (1986) 1.05
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst (1992) 1.04
Carbon monoxide-induced Parkinsonism. J Neurol Sci (1972) 1.03
Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med (1992) 1.01
Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol (1999) 1.01
Exercise hyperventilation in patients with McArdle's disease. J Appl Physiol Respir Environ Exerc Physiol (1982) 1.01
The prolonged exercise test. Neurology (1979) 1.01
Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1994) 1.00
Clinical application of PET for the evaluation of brain tumors. J Nucl Med (1991) 0.99
Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol (2005) 0.99
Muscle denervation in peripheral arterial disease. Neurology (1992) 0.99
The NF-kappaB inhibitor diethyldithiocarbamate (DDTC) increases brain cell death in a transient middle cerebral artery occlusion model of ischemia. Brain Res Bull (2001) 0.98
Amyloid-associated muscle pseudohypertrophy. Arch Neurol (1982) 0.97
Rathke's cleft cyst. J Neurol Neurosurg Psychiatry (1972) 0.97
Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: diagnosis and treatment with alpha tocopherol. J Pediatr (1982) 0.97
Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol (1980) 0.97
Experimental autoimmune myositis in SJL/J mice. Clin Exp Immunol (1987) 0.96
Ultrastructural and histochemical abnormalities of skeletal muscle in patients with chronic vitamin E deficiency. Neurology (1983) 0.96
Late-onset X-linked recessive spinal and bulbar muscular atrophy. Muscle Nerve (1979) 0.95
Distribution of capillaries in normal and diseased human skeletal muscle. Muscle Nerve (1986) 0.95
Depressed ventilatory response in oculocraniosomatic neuromuscular disease. Neurology (1976) 0.95
Double trouble: combined myophosphorylase and AMP deaminase deficiency in a child homozygous for nonsense mutations at both loci. Neuromuscul Disord (1995) 0.95
Immunohistochemical characterization of the mononuclear cells infiltrating muscle of patients with inflammatory and noninflammatory myopathies. Clin Immunol Immunopathol (1984) 0.95
Glioblastoma multiforme after radiotherapy for acromegaly. Neurosurgery (1983) 0.94
Tubular aggregates: sarcoplasmic reticulum origin, calcium storage ability, and functional implications. Muscle Nerve (1985) 0.94
Gadopentetate-dimeglumine-enhanced MR imaging of gliomatosis cerebri: appearance mimicking leptomeningeal tumor dissemination. AJNR Am J Neuroradiol (1990) 0.94
Observations on the efficacy of L-dopa in progressive supranuclear palsy. Eur Neurol (1971) 0.94
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer Res (1994) 0.94
Selection bias in clinical trials of anaplastic glioma. Ann Neurol (1989) 0.94
Acoustic analysis of voices of patients with neurologic disease: rationale and preliminary data. Ann Otol Rhinol Laryngol (1988) 0.93
The ALS patient care database: goals, design, and early results. ALS C.A.R.E. Study Group. Neurology (2000) 0.92
The relationship of age to outcome in myasthenia gravis. Neurology (1990) 0.92
Autonomic dysfunction and adrenocortical unresponsiveness to ACTH. J Child Neurol (1988) 0.92
Neurology practice patterns in Colorado. Neurology (1987) 0.91
Extrajunctional acetylcholine receptors. Alterations in human and experimental neuromuscular diseases. Arch Neurol (1976) 0.91
Facioscapulohumeral dystrophy associated with hearing loss and Coats syndrome. Ann Neurol (1982) 0.91
Antibodies to nucleic acids in myasthenia gravis. Int Arch Allergy Appl Immunol (1976) 0.91
p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer (1995) 0.91
Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: clinical and muscle biopsy findings and treatment with alpha-tocopherol. Ann N Y Acad Sci (1982) 0.91
Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol (1996) 0.91
Respiratory improvement by muscle training in adult-onset acid maltase deficiency. Muscle Nerve (1983) 0.90
Quantitative histopathology of the inflammatory myopathies. Arch Neurol (1986) 0.90
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst (1992) 0.90
Tubular aggregates. Their association with neuromuscular diseases, including the syndrome of myalgias/cramps. Arch Neurol (1985) 0.90
Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines. Carcinogenesis (1991) 0.89
Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery (1986) 0.89
Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells. Br J Cancer (1997) 0.89
Fatty acid oxidation intermediates and the effect of fasting on oxidation in red and white skeletal muscle. Muscle Nerve (1983) 0.88
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res (1996) 0.88
Chronic valproate administration reduces fasting ketonemia in children. Neurology (1983) 0.88
Effects of selective and nonselective beta-adrenergic blockade on mechanisms of exercise conditioning. Circulation (1986) 0.87
Biochemical and physiologic consequences of carnitine palmityltransferase deficiency. Muscle Nerve (1979) 0.87
Malignant glioma--timing of response to radiation therapy. Int J Radiat Oncol Biol Phys (1993) 0.87